As we’ve discussed on this blog before, the U.S. Food and Drug Administration’s (FDA) accelerated approval program has served as a critical lifeline for patients with serious and life-threatening conditions. The program was originally established at the urging of patient advocates during the height of the HIV/AIDS epidemic, in which patients waited years for the FDA to review and approve new treatments. From its inception three decades ago, the pathway’s purpose has always been to get medicines to patients most in need, especially those who lack any viable treatment options. Without accelerated approval, patients in need would have fewer or no treatment options.
Accelerated approval can be based on a surrogate endpoint which we’ve previously written about. A surrogate endpoint is a measure, such as laboratory measurement, that is expected to predict clinical benefit. When treating patients with life-threatening diagnoses, researchers may use surrogate endpoints in clinical trials when demonstrating a clinical outcome might take a long time to study, or when the severity or duration of a disease course would make extended or large studies unethical or impossible. This saves valuable time for patients with serious and life-threatening diseases without other treatment options, making new medicines available sooner.
One common misconception is medicines receiving accelerated approval are merely “conditional” and are not as safe and effective as medicines receiving traditional approval. This is not true.
Medicines with accelerated approval must adhere to the same standards for establishing safety and effectiveness as medicines receiving traditional approval. This includes requiring sponsors to provide substantial evidence of effectiveness based on “adequate” and “well-controlled” clinical investigations. Congress itself has made clear through statute accelerated approval does not alter the standards of evidence required for a new medicine to be approved.
To see how impactful the pathway is for patients, look no further than rare diseases.
From 1992 through about 2010, rare disease medicines made up 24.7% of the medicines with accelerated approval. Rare diseases are among some of the most difficult diseases to study for a range of factors, which include disease complexity, lack of timely diagnosis, and small or geographically dispersed patient populations that make trial recruitment and retainment a challenge. As such, rare diseases remain an area of significant unmet medical need with over 90% of the known rare diseases having no approved treatment option available. These factors combined make accelerated approval a critical tool for rare disease patients in urgent need of innovative medicines.
Policies that would penalize medicines with accelerated approval by imposing additional rebates or making other changes to reimbursement could mean that patients would have to wait an average of 3.2 years longer to access these innovative therapies. For patients with serious or life-threatening diseases, that is time they don’t have to waste. Since its creation, accelerated approval has been a resounding success in expediting patient access to lifesaving medicines and addressing unmet medical needs. Let’s make sure we don’t do anything to slow that progress.
To learn more about the importance of the accelerated approval pathway, click here.
Andrew Powaleny
Andrew Powaleny is the Deputy Vice President of Public Affairs at PhRMA, where he leads communications on scientific, regulatory and intellectual property issues, highlighting the biopharmaceutical industry’s efforts in developing innovative medicines and vaccines while promoting an environment that encourages necessary risk-taking. For five years starting in 2019, he launched and led PhRMA’s grassroots initiative, Voters for Cures, bringing patients and caregivers together to advocate for access to medicine and biopharmaceutical innovation. He also co-founded and co-chaired PRIDE Umbrella, a resource group for LGBTQ+ individuals. Prior to joining PhRMA in 2015, Andrew worked as a communications consultant in Washington, D.C., and as Deputy Press Secretary for the U.S. House Committee on Energy and Commerce under Chairman Fred Upton. He holds a degree in public policy and government from Eastern Connecticut State University, with a minor in music. Outside of work, Andrew enjoys exercise, musical theater and mentoring college students through The Fund for American Studies alumni association.
Andrew Powaleny
Mass compounding puts patients at risk
World Sickle Cell Day: Recognizing the promise of gene therapy
Celebrating rare disease innovation: Progress and the path forward
Advancing patient care: A look at new medicines approved in 2025
Knockoffs of FDA-approved drugs put patients at risk
PDUFA: Essential to America’s edge in drug development and patient access
4 things to know on Rare Disease Day
Major drug compounder is spending millions on misleading Super Bowl ad
Preventing and fighting disease: A look at the biopharmaceutical progress made for patients in 2024
More oversight needed of unapproved medicines that threaten patients’ health
The use of real-world data in drug development
New analysis: Accelerated approval pathway is changing lives in underserved communities
Watch: A conversation with Dr. Mike Ybarra on Rare Disease Day
Novel treatments and vaccines approved for U.S. patients in 2023 reach five-year high
Florida’s importation plan puts patients in danger
The Biopharmaceutical Industry Still Needs Clarity from the FDA on Orange Book Listings
Don't close the door on rare disease research
Decentralized clinical trials and the future of drug development
New report shows how the Inflation Reduction Act stifles innovation for small molecule medicines
How FDA’s modernization strategy could improve drug development
A guide to MedPAC’s Part B vote today
FDA should remain the authority on the safety and effectiveness of medicines
MedPAC proposal threatens access to medicines in Part B
Celebrating 40 years of the Orphan Drug Act on Rare Disease Day
Novel medicines approved in 2022 offer increased treatment options for patients
What you should know about real-world evidence and drug development
Three things to know about the accelerated approval pathway
PDUFA and BsUFA reauthorizations are wins for patients
Recognizing National Sickle Cell Awareness Month
Word of the Month: Biomarkers and surrogate endpoints
Ensuring timely reauthorization of PDUFA and BsUFA
The accelerated approval pathway: Helping patients with serious or life-threatening diseases
Biopharmaceutical research and development has ushered in a decade of innovation in rare disease
The importance of timely PDUFA and BsUFA reauthorization
ICYMI: New approvals by the FDA in 2021 offer greater treatment options for patients
New Report: Nearly 800 new medicines in development to treat rare diseases
3 things to know about the importance of post-approval research and development
Biosimilar User Fee Act (III) Performance Goals Letter will help increase options for patients and promote competition
Meeting Tomorrow: Looking ahead to PDUFA VII
The impact of monoclonal antibodies and COVID-19 recovery
PDUFA VII is critical for future biopharmaceutical innovation and for patients
How strengthening the biosimilar marketplace benefits patients
The FDA Office of Minority Health and Health Equity: Working to advance health equity through diversity in research
2020 FDA approvals show innovation despite COVID-19 pandemic challenges
Nearly 400 cell and gene therapies in development to target a broad range of diseases
Rare Disease Day 2020: Progress toward cures
ICYMI: 2019 brings innovative medicines to patients
PhRMA comments to Congress on Cures 2.0 call to action
Speaker Pelosi’s drug pricing plan could result in 56 fewer new medicines over 10 years
Pelosi’s radical plan would leave patients with sickle cell disease behind
Pelosi’s radical plan would leave patients with rare pediatric diseases behind
ICYMI: Fighting for a cure to ALS
Guest Post: Using the patient voice to go boldly
IP Explained: How Hatch-Waxman successfully balances affordability and innovation
New report shows nearly 20 innovative medicines in development for sickle cell disease
Guest post: Hearing from patients on Rare Disease Day
Rare Disease Day: Unmet medical need inspires biopharmaceutical innovation
Why state drug importation pilot programs don’t work
Putting 2018 medicine approvals in context
FDA needs best and brightest to advance a new era of medicine with America’s biopharmaceutical companies
Balancing innovation and competition in the biologics marketplace
New analysis shows that more medicines worldwide are available to U.S. patients
ICYMI: Orphan drug development brings unique challenges
Spending on medicines grew less than one percent in 2017
Rare Disease Day: Unmet need inspires innovation
Innovation comes in many forms, including new and expanded uses of existing medicines
ICYMI: Why 2017 medicine approvals matter
New surveys find payers and providers want more data from biopharmaceutical companies
Supporting opportunities for enhanced competition in the marketplace
VIDEO: PhRMA CEO discusses industry response to opioid crisis on Mornings with Maria
Opportunities to build upon enhanced competition for medicines in the marketplace
Why reauthorization of PDUFA matters
A critical opportunity to prevent prescription drug abuse
Guest Post: The importance of a modern FDA in drug discovery
Guest Post: Debra of America on Epidermolysis Bullosa
Guest Post: Room for optimism in ALS research
Guest Post: A Cure for Ellie on Leukodystrophy-LBSL
Guest Post: Epilepsy Foundation on rare diseases
Rare Disease Day: Accelerating innovation for patients in need
Setting the record straight on accelerated approval
FDA
Rare Diseases
Accelerated Approval
Setting the record straight on accelerated approval
Setting the record straight on accelerated approval